We are live on ! Find out more
PPBT

Purple Biotech
PPBT

15 hedge funds and large institutions have $1.86M invested in Purple Biotech in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

48% less funds holding

Funds holding: 29 → 15 (-14)

66% less capital invested

Capital invested by funds: $5.52M → $1.86M (-$3.66M)

74% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 19

Holders
15
Holders Change
-14
Holders Change %
-48.28%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
3
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SFI
Susquehanna Fundamental Investments
Pennsylvania
+$178K
2
Goldman Sachs
Goldman Sachs
New York
+$70.4K
3
Morgan Stanley
Morgan Stanley
New York
+$37.1K
4
ECM
ETrade Capital Management
Virginia
+$32.1K
5
NSIM
North Star Investment Management
Illinois
+$2.47K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$400K
2
TSS
Two Sigma Securities
New York
-$281K
3
UBS Group
UBS Group
Switzerland
-$161K
4
VF
Virtu Financial
New York
-$119K
5
JMPWA
JP Morgan Private Wealth Advisors
California
-$56K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$1.53M – – –
SFI
2
Susquehanna Fundamental Investments
Pennsylvania
$127K +$178K +144 New
ECM
3
ETrade Capital Management
Virginia
$76K +$32.1K +26 +43%
Goldman Sachs
4
Goldman Sachs
New York
$50K +$70.4K +57 New
Morgan Stanley
5
Morgan Stanley
New York
$27K +$37.1K +30 +3,000%
UBS Group
6
UBS Group
Switzerland
$11K -$161K -130 -92%
BFC
7
Bedel Financial Consulting
Indiana
$11K -$2.47K -2 -13%
TPWA
8
TRUE Private Wealth Advisors
Oregon
$10K – – –
ASN
9
Advisory Services Network
Georgia
$9K – – –
Osaic Holdings
10
Osaic Holdings
Arizona
$4K – – –
RFA
11
Reilly Financial Advisors
California
$2K +$2.47K +2 New
YAL
12
Your Advocates Ltd
Texas
$2K +$2.47K +2 New
IA
13
IFP Advisors
Florida
$1K -$1.24K -1 -50%
NSIM
14
North Star Investment Management
Illinois
$1K +$2.47K +2 New
Citadel Advisors
15
Citadel Advisors
Florida
– -$400K -180 Closed
TSS
16
Two Sigma Securities
New York
– -$281K -127 Closed
VF
17
Virtu Financial
New York
– -$119K -54 Closed
JMPWA
18
JP Morgan Private Wealth Advisors
California
– -$56K -25 Closed
Millennium Management
19
Millennium Management
New York
– -$45K -20 Closed
SG
20
StoneX Group
New York
– -$39K -18 Closed
RJFSA
21
Raymond James Financial Services Advisors
Florida
– -$30K -14 Closed
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
– -$30K -14 Closed
HWA
23
HCR Wealth Advisors
California
– -$18K -10 Closed
Jane Street
24
Jane Street
New York
– -$24K -10 Closed
KWM
25
Kingsview Wealth Management
Oregon
– -$18K -8 Closed
1
2

PPBT Hedge Fund Activity: Q3 2020 in Review

15 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q3 2020, worth a combined $1.86M — down 66% from $5.52M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of PPBT and 5 opened new positions — a net loss of 14 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Susquehanna Fundamental Investments, opening a new position worth an estimated $178K. The largest seller was Citadel Advisors, exiting entirely with an estimated $400K sold.

  • 15 institutional investors held Purple Biotech (PPBT) as of Q3 2020, down from 29 in Q2 2020.
  • Funds reported $1.86M of Purple Biotech stock for Q3 2020, down 66% quarter-over-quarter.
  • 5 funds opened new Purple Biotech positions in Q3 2020 and 19 closed out, a net change of -14 holders.
  • The largest Purple Biotech buyer in Q3 2020 was Susquehanna Fundamental Investments, an estimated $178K added.
  • The largest Purple Biotech seller in Q3 2020 was Citadel Advisors, an estimated $400K sold.

Based on aggregated 13F filings for Q3 2020.